Hanmi Pharm Strikes Up to $2.3 Billion Licensing Deal With Genentech for Muscle‑Sparing Obesity Candidate HM17321
Hanmi Pharm. Co., Ltd. announced it has entered into an exclusive licensing agreement with Genentech,...
Metabolic disease
Hybio Files First tirzepatide Generic ANDA in China, Challenging Eli Lilly’s GLP-1 Dominance
Shenzhen Hybio Pharmaceutical Co., Ltd. (SHE: 300199) announced it has submitted a Class 4 Chemical Abbreviated New...
Novo Nordisk Launches Wegovy Oral Tablets in UAE – First International Market Outside US for Semaglutide Weight Management Therapy
Novo Nordisk A/S (NYSE: NVO) announced the market launch of Wegovy (semaglutide) oral tablets in...
China‑SCO Metabolic Disease Cooperation Center Established at Ruijin Hospital – First National‑Level SCO Platform in Shanghai
The China‑Shanghai Cooperation Organization (SCO) Metabolic Disease Cooperation Center was officially established at Ruijin Hospital,...
United Labs’ UBT251 Achieves 19.7% Weight Loss in Phase II – Triple‑Target GLP‑1/GIP/GCG Agonist Shows Blockbuster Potential
United Laboratories International Holdings Ltd (HKG: 3933) announced completion of a Phase II clinical trial for...
Novo Nordisk to Cut Semaglutide List Prices by 35‑50% – Wegovy, Ozempic, Rybelsus Standardized at $675/Month
Novo Nordisk (NYSE: NVO) announced that, effective January 1, 2027, it will lower Wholesale Acquisition Cost (list prices)...
Novo Nordisk to Launch Wegovy Vial Version in Price War with Eli Lilly
Novo Nordisk A/S (NYSE: NVO) announced plans to launch a vial version of Wegovy (semaglutide), shifting...
Eli Lilly’s Mounjaro Wins NMPA Monotherapy Approval for Type 2 Diabetes in China
Eli Lilly and Company (NYSE: LLY) announced that the National Medical Products Administration (NMPA) has approved...
CSPC Pharma Signs $18.5B AstraZeneca Deal for Weight Management Portfolio
CSPC Pharmaceutical Group Ltd (HKG: 1093) announced a landmark partnership with AstraZeneca Plc (AZ, NASDAQ: AZN) to...
Insilico Medicine Partners with Qilu Pharma on AI Drug Development
Insilico Medicine (HKG: 3696), a China‑based generative AI‑driven biotech, announced a strategic partnership with Qilu...
Ascletis Pharma Advances ASC37 Oral Triple Agonist for Obesity, Targets Q2 2026 FDA IND
Ascletis Pharma Inc. (HKG: 1672) announced it has selected ASC37 oral tablets, its first GLP‑1R/GIPR/GCGR...
Novo Nordisk’s Semaglutide 7.2 mg sNDA Submitted for Weight Management
Novo Nordisk A/S (NYSE: NVO) announced the submission of a supplemental New Drug Application (sNDA)...
CSPC’s JMT206 Wins NMPA Nod for ActRII-Targeted Weight Management
CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its self‑developed recombinant fully human anti‑ActRIIA/IIB monoclonal...
SanegeneBio & Eli Lilly Sign Global Partnership to Advance RNAi Therapies for Metabolic Diseases
SanegeneBio, a biotechnology company specializing in RNAi therapeutics, today announced a global research collaboration and...